[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE486956T1 - T-zellrezeptor vb-db-jb-sequenz und verfahren für ihren nachweis - Google Patents

T-zellrezeptor vb-db-jb-sequenz und verfahren für ihren nachweis

Info

Publication number
ATE486956T1
ATE486956T1 AT00922309T AT00922309T ATE486956T1 AT E486956 T1 ATE486956 T1 AT E486956T1 AT 00922309 T AT00922309 T AT 00922309T AT 00922309 T AT00922309 T AT 00922309T AT E486956 T1 ATE486956 T1 AT E486956T1
Authority
AT
Austria
Prior art keywords
oligonucleotide
sequence
motif
nucleic acid
found
Prior art date
Application number
AT00922309T
Other languages
English (en)
Inventor
Jingwu Zhang
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE486956T1 publication Critical patent/ATE486956T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
AT00922309T 1999-02-23 2000-02-22 T-zellrezeptor vb-db-jb-sequenz und verfahren für ihren nachweis ATE486956T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12131199P 1999-02-23 1999-02-23
PCT/US2000/040006 WO2000050641A1 (en) 1999-02-23 2000-02-22 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION

Publications (1)

Publication Number Publication Date
ATE486956T1 true ATE486956T1 (de) 2010-11-15

Family

ID=22395857

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00922309T ATE486956T1 (de) 1999-02-23 2000-02-22 T-zellrezeptor vb-db-jb-sequenz und verfahren für ihren nachweis

Country Status (16)

Country Link
US (1) US6303314B1 (de)
EP (1) EP1159457B1 (de)
JP (2) JP2003504005A (de)
KR (1) KR100479648B1 (de)
CN (1) CN1355852A (de)
AT (1) ATE486956T1 (de)
AU (2) AU774952B2 (de)
BR (1) BR0008966A (de)
CA (1) CA2362099C (de)
DE (1) DE60045188D1 (de)
HK (1) HK1044965A1 (de)
HU (1) HUP0202574A2 (de)
NZ (1) NZ513630A (de)
PL (1) PL364917A1 (de)
RU (1) RU2251552C2 (de)
WO (1) WO2000050641A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030086983A (ko) * 2000-08-22 2003-11-12 베일러 칼리지 오브 메디신 티 세포 리셉터 브이 베타 - 디 베타 - 제이 베타 서열과그것을 검출하는 방법
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US7744893B2 (en) 2002-06-05 2010-06-29 Baylor College Of Medicine T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
DE60330780D1 (de) * 2002-06-05 2010-02-11 Opexa Pharmaceuticals Inc Sequenzen des t-zellrezeptors cdr3 und nachweisverfahren
US7695713B2 (en) * 2002-08-08 2010-04-13 Baylor College Of Medicine Isolation and identification of T cells
WO2004060145A2 (en) * 2002-12-31 2004-07-22 Baylor College Of Medicine Isolation and identification of cross-reactive t cells
ATE538809T1 (de) 2003-06-27 2012-01-15 Int Inst Cancer Immunology Inc Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
US20100003228A1 (en) * 2006-05-05 2010-01-07 Willimas Jim C T-cell vaccine
WO2008108257A1 (ja) 2007-03-05 2008-09-12 International Institute Of Cancer Immunology, Inc. 癌抗原特異的ｔ細胞のレセプター遺伝子およびそれによりコードされるペプチドならびにそれらの使用
ES2725003T3 (es) 2007-03-28 2019-09-18 Signal Diagnostics Sistema y método de análisis de alta resolución de ácidos nucleicos para detectar variaciones de secuencia
US10669574B2 (en) 2008-11-18 2020-06-02 XCR Diagnostics, Inc. DNA amplification technology
WO2013002086A1 (ja) 2011-06-28 2013-01-03 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
CN102875667B (zh) * 2012-09-05 2014-07-09 南方医科大学 一种HIV-1肽Env120-128特异性TCR、其重组逆转录病毒载体与应用
KR102323375B1 (ko) 2013-10-09 2021-11-08 플루어레센트릭 인코포레이티드 다중 프로브
EP3262189B1 (de) * 2015-02-27 2021-12-08 Becton, Dickinson and Company Verfahren zur strichcodierung von nukleinsäuren zur sequenzierung
EP3577234B1 (de) * 2017-01-31 2024-03-20 Ludwig Institute For Cancer Research Ltd. Verfahren zur sequenzierung von erweiterten immunzellrezeptoren

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836656A1 (de) 1988-10-27 1990-05-03 Boehringer Mannheim Gmbh Neue digoxigenin-derivate und ihre verwendung
US5614192A (en) 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
AU3418893A (en) 1991-12-24 1993-07-28 Immune Response Corporation, The Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
AU2701895A (en) 1994-06-07 1996-01-05 Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
WO1996018105A1 (en) * 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor

Also Published As

Publication number Publication date
PL364917A1 (en) 2004-12-27
JP2003504005A (ja) 2003-02-04
AU2004220763A1 (en) 2004-11-11
AU774952B2 (en) 2004-07-15
CN1355852A (zh) 2002-06-26
KR100479648B1 (ko) 2005-03-30
EP1159457A4 (de) 2004-11-17
WO2000050641A1 (en) 2000-08-31
BR0008966A (pt) 2002-10-15
EP1159457A1 (de) 2001-12-05
EP1159457B1 (de) 2010-11-03
RU2251552C2 (ru) 2005-05-10
DE60045188D1 (de) 2010-12-16
CA2362099A1 (en) 2000-08-31
HK1044965A1 (zh) 2002-11-08
US6303314B1 (en) 2001-10-16
HUP0202574A2 (en) 2002-12-28
NZ513630A (en) 2001-09-28
CA2362099C (en) 2014-05-13
KR20020013503A (ko) 2002-02-20
JP2007308502A (ja) 2007-11-29
AU4251200A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
ATE486956T1 (de) T-zellrezeptor vb-db-jb-sequenz und verfahren für ihren nachweis
ES2242291T5 (es) Análogos de nucleósidos bicíclicos y tricíclicos, nucleótidos y oligonucleótidos
MX9803308A (es) Metodos y composiciones para la deteccion de secuencias especificas de nucleotidos.
ES2385867T1 (es) Método y kit para la cuantificación cromosómica molecular
WO1999049082A3 (en) Modified nucleotides and methods useful for nucleic acid sequencing
WO2001077378A3 (en) Diagnosis of diseases associated with dna adducts
ES2150103T3 (es) Oligonucleotidos de amplificacion de acido nucleico y sondas para borrelia asociados con la enfermedad de lyme.
WO1999023250A3 (de) Spezifisches und sensitives nukleinsäurenachweisverfahren
DE60038109D1 (de) Verfahren zur Analyse von AFLP Reaktionsmischungen unter Verwendung von Primer Verlängerungstechniken
RU2001125895A (ru) Vбета-Dбета-Jбета-последовательность Т-клеточного рецептора и способы ее обнаружения
AU1204600A (en) Systems and methods for sequencing by hybridization
DE69815370D1 (de) Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen
MX9709338A (es) Receptor de transmembrana-siete de tipo c5a.
BR0017319A (pt) Seq ência vbeta-dbeta-jbeta receptora de células t e métodos para sua detecção
RU2004139045A (ru) Последовательности cdr3 t-клеточного рецептора и способы детекции
EP1683862A4 (de) Mikroarray zur beurteilung der neuroblastomprognose und verfahren zur beurteilung der neuroblastomprognose
WO1996028549A3 (en) Hyaluronan receptor expressed in human umbilical vein endothelial cells
KR20220076453A (ko) 올리고-dT 역전사된 RNA로부터 TCR 알파 및 베타 쇄 VDJ를 회수하는 프로브 포획 방법
JP2005528910A5 (de)
ATE332981T1 (de) Einzelsträngige oligonukleotide, sonden, primer und ein vefahren zur detektion von spirochaeten
MXPA00004675A (es) Metodos y composiciones para la deteccion de secuencias nucleotidicas especificas.
WO2003014342A3 (en) Identification of a dna variant associated with adult type hypolactasia
DE69931754D1 (de) Nukleinsäurefragmente, rekombinante vektoren, welche diese enthalten und verfahren zum unterstützen der expression von strukturellen genen durch anwendung derselben
MX9709337A (es) Receptor p2u purinergico humano novedoso.
Malyarchuk et al. The T4336C variant is a marker of mitochondrial subhaplogroup H1, a common component of the Russian and German gene pools

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties